Deguelin (Synonyms: (-)cisDeguelin) |
Catalog No.GC15484
One-Click Copy Product Info
|
Deguelin is one of four major naturally occurring rotenoids isolated from root extracts and is best recognized as a NADH: ubiquinone oxidoreductase (complex I) inhibitor, resulting in significant alterations in mitochondrial function.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 522-17-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Deguelin is one of four major naturally occurring rotenoids isolated from root extracts and is best recognized as a NADH: ubiquinone oxidoreductase (complex I) inhibitor, resulting in significant alterations in mitochondrial function[1]. Deguelin has shown promising results in targeting the hallmarks of tumor progression via inducing tumor apoptosis, cell cycle arrest, and inhibition of angiogenesis and metastasis[2][3][5].
In vitro, Deguelin was applied on head and neck squamous cell carcinoma Hep-2 cells at a various concentration (10, 25, 50, 100 and 200µM) for 72 hours or for different time points (12, 24, 48 and 72 hours) with fixed concentration (100µM). Deguelin administration caused significant cell viability loss and growth inhibition in both dose- and time- dependent manner[3]. Deguelin (0.1 to 1.6nM) inhibited nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis in primary bone marrow-derived macrophages (BMMs) for up to 7 days treatment[4].
In vivo, Deguelin (2 or 4mg/kg), when injected intraperitoneally daily for 21 days, reduced the in vivo tumor growth of human breast cancer cell MDA-MB-231 cells transplanted subcutaneously in athymic mice[5]. Deguelin (1 or 4mg/kg) was given by intraperitoneal injection into ovalbumin-preinduced asthmatic model mice 1h before each OVA aerosol challenge for 3 days. Deguelin effectively reduced OVA-induced inflammatory cell recruitment in BALF, decreased inflammatory cell infiltration and mucus production in lungs, suppressed airway hyperresponsiveness, and inhibited serum immunoglobulin and Th2 cytokines in asthmatic model[6]. Deguelin (20mg/kg) were immediately injected intraperitoneally into acetaminophen (APAP) incuded acute liver failure model mice. Deguelin exerted hepatoprotective effects against APAP-induced liver injury by enhancing hepatic glutathione (GSH) levels, reducing oxidative stress markers such as malondialdehyde (MDA) and reactive oxygen species (ROS), and lowering hepatic levels of the toxic APAP metabolite NAPQI and APAP-protein adducts[7].
References:
[1] Boyd J, Han A. Deguelin and Its Role in Chronic Diseases. Adv Exp Med Biol. 2016:929:363-375.
[2] Tuli H S, Mittal S, Loka M, et al. Deguelin targets multiple oncogenic signaling pathways to combat human malignancies. Pharmacol Res. 2021 Apr:166:105487.
[3] Yang Y L, Ji C, Bi Z G, et al. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. PLoS One. 2013;8(1):e54736.
[4] Zhang T, Zhao K X, Han W Q, et al. Deguelin inhibits RANKL-induced osteoclastogenesis in vitro and prevents inflammation-mediated bone loss in vivo. J Cell Physiol. 2019 Mar;234(3):2719-2729.
[5] Mehta R, Katta H, Alimirah F,et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One. 2013 Jun 10;8(6):e65113.
[6] Bao Z, Zhang P, Yao Y N, et al. Deguelin Attenuates Allergic Airway Inflammation via Inhibition of NF-κb Pathway in Mice. Int J Biol Sci. 2017 Apr 8;13(4):492-504.
[7] Gong S H, Zeng Y N, Ze Wang Z, et al. Intestinal deguelin drives resistance to acetaminophen-induced hepatotoxicity in female mice. Gut Microbes. 2024 Jan-Dec;16(1):2404138.
| Cell experiment [1]: | |
Cell lines | Primary bone marrow‐derived macrophages (BMMs) |
Preparation Method | The BMMs were seeded in six‐well plates at a density of 1 × 105 cells/well and cultured in complete α‐MEM supplemented with 25ng/ml M‐CSF and 100ng/ml RANKL. After RANKL‐induced osteoclastogenesis, the BMMs were treated with different doses of Deguelin (0, 0.1, 0.2, 0.4, 0.8, 1.6nM) for 7 days. |
Reaction Conditions | 0-1.6nM; 7 days |
Applications | Deguelin inhibited osteoclasts formation in a dose‐ and time‐dependent manner by inhibiting the NF‐κB signaling pathway. |
| Animal experiment [2]: | |
Animal models | Six to seven weeks old female athymic mice (nu/nu) |
Preparation Method | Animals receiving either 1) vehicle as a control 2) Deguelin treatment at 2mg/kg bodyweight dose or 3) Deguelin at 4mg/kg body weight. Each group consisted of 10 animals. Vehicle or Deguelin was administered through i.p. injection daily for 21 days. |
Dosage form | 2 or 4mg/kg; i.p; daily for 21 days |
Applications | Deguelin Inhibited in vivo growth of MDA-MB-231 cells and reduced nuclear PCNA, EGFR (both cytoplasmic and membrane), pERK c-Met (nuclear), p-AKT and cytoplasmic and nuclear NFkB, nuclear Survivin protein expressions in xenograft. |
References: | |
| Cas No. | 522-17-8 | SDF | |
| Synonyms | (-)cisDeguelin | ||
| Chemical Name | (7aS,13aS)-9,10-dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one | ||
| Canonical SMILES | [H][C@]12[C@](C(C(C=CC3=C4C=CC(C)(C)O3)=C4O2)=O)([H])C5=CC(OC)=C(OC)C=C5OC1 | ||
| Formula | C23H22O6 | M.Wt | 394.42 |
| Solubility | DMF: 30 mg/ml,DMF:PBS (pH 7.2) 1:4: 0.33 mg/ml,DMSO: 25 mg/ml,Ethanol: Insoluble* | Storage | Store at 4°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5354 mL | 12.6768 mL | 25.3537 mL |
| 5 mM | 507.1 μL | 2.5354 mL | 5.0707 mL |
| 10 mM | 253.5 μL | 1.2677 mL | 2.5354 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)